{
  "pmcid": "5498377",
  "sha256": "77514bbdf288429c74ef81b27a21f0914dcb54aacea078e4c7c19427d6662257",
  "timestamp_utc": "2025-11-09T22:46:34.357395+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 11.942500000000003,
    "reading_ease": 36.15750000000003,
    "word_count": 240
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Tranexamic Acid Administration Routes in Total Knee Arthroplasty"
      },
      "Trial_Design": {
        "score": 2,
        "evidence": "A total of 376 patients undergoing TKA between March 2014 and March 2015 were randomised into four groups"
      },
      "Participants": {
        "score": 2,
        "evidence": "patients undergoing TKA"
      },
      "Intervention": {
        "score": 2,
        "evidence": "randomised into four groups: IV only, IA only, low-dose combined (IV + IA injection of 1 g), and high-dose combined (IV + IA injection of 2 g)"
      },
      "Objective": {
        "score": 1,
        "evidence": "aimed to compare the efficacy of tranexamic acid in reducing total blood loss and allogeneic transfusion rates among different administration routes in total knee arthroplasty (TKA)"
      },
      "Method_Outcome": {
        "score": 1,
        "evidence": "The primary outcome was total blood loss"
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was performed using a computer-generated sequence with allocation concealment"
      },
      "Blinding": {
        "score": 1,
        "evidence": "Blinding was applied to outcome assessors"
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "A total of 376 patients undergoing TKA between March 2014 and March 2015"
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "mean differences = 199 mL [95% CI, 116–283 mL], p < 0.001; 121 mL [95% CI, 38–205 mL], p = 0.001; 131 mL [95% CI, 47–214 mL], p < 0.001"
      },
      "Harms": {
        "score": 1,
        "evidence": "One patient in the IV-only group developed a symptomatic pulmonary embolism"
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Trial registration: [Trial registration number]"
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: [Source of funding]"
      }
    },
    "total_score": 18,
    "max_score": 25
  }
}